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Cardiovascular disease is a leading cause of death worldwide. Since adult cardiac cells are limited 
in their proliferation, cardiac tissue with dead or damaged cardiac cells downstream of the 
occluded vessel does not regenerate after myocardial infarction. The cardiac tissue is then replaced 
with nonfunctional fibrotic scar tissue rather than new cardiac cells, which leaves the heart weak. 
The limited proliferation ability of host cardiac cells has motivated investigators to research the 
potential cardiac regenerative ability of stem cells. Considerable progress has been made in this 
endeavor. However, the optimum type of stem cells along with the most suitable matrix-material 
and cellular microenvironmental cues are yet to be identified or agreed upon. This review presents 
an overview of various types of biofunctional materials and biomaterial matrices, which in 
combination with stem cells, have shown promises for cardiac tissue replacement and 
reinforcement. Engineered biomaterials also have applications in cardiac tissue engineering, in 
which tissue constructs are developed in vitro by combining stem cells and biomaterial scaffolds 
for drug screening or eventual implantation. This review highlights the benefits of using 
biomaterials in conjunction with stem cells to repair damaged myocardium and give a brief 
description of the properties of these biomaterials that make them such valuable tools to the field.
Graphical Abstract
Keywords
angiogenesis; hydrogel; myocardial infarction; nanomedicine; stem cells
 1. Introduction
Myocardial infarction (MI) is one of the main causes of morbidity and mortality around the 
world.[1] Each year around one million deaths occur due to heart failure in the United States 
alone.[2] MI results from the obstruction of cardiac vessels which halts blood flow to part of 
the heart causing damage to that portion of the myocardium. Blood flow can be restored in 
the occluded tissues by balloon angioplasty, stenting, and cardiac bypass surgeries; however, 
the damaged cardiac tissue does not self-regenerate and the heart remains weak. Recent 
developments in stem cell research aim to restore injured myocardium by regenerative 
medicine and tissue engineering methods.
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Adult cardiomyocytes are terminally differentiated cells that have a minimal proliferation 
capacity and that cannot be extracted in sufficient numbers. A potential alternative to 
cardiomyocytes for cardiac repair is stem cells—a self-renewable and differentiable cell 
source that has provoked increased cardiac function following cell-based therapy.[3] Some 
types of stem cells, such as mesenchymal stem cells (MSCs) and cardiac stem cells (CSCs), 
have made it to human trials. Recently, attention has turned toward the potential therapeutic 
effects of partially differentiated stem cells such as adipose-derived adult stem cells and 
endothelial progenitor cells. Endothelial progenitor cells were shown to directly trigger pro-
angiogenic factors and healing responses that may be of potential use for tissue engineering 
and regenerative medicine. Embryonic stem cells (ESCs) are another source of stem cells 
that have engendered propitious results in cardiac regeneration. ESCs are pluripotent, are 
easily handled and proliferated, and were shown to differentiate into cardiomyocytes.[4] 
Animal studies have demonstrated some repairs in damaged heart muscle using this cell line. 
Despite positive results from ESCs, numerous ethical controversies have driven research 
away from them. A solution to these concerns may be found in somatic cells that have been 
“reprogrammed” and found to mimic ESCs engineered induced pluripotent stem cells 
(iPSCs).[5] They are among the most recent ESC alternative sources under investigation in 
animal models. More effective cardiac therapy for any of the above stem cells has been 
achieved through the careful regulation of stem cell environment in conjunction with the 
addition of growth factors and chemokines.
Regenerative medicine and tissue engineering techniques are at the center of the most 
promising “nextgeneration” therapies for MI.[3] Regenerative medicine is intended to repair 
the damaged cardiac tissue in vivo by injecting cells directly into the heart. Several delivery 
routes have been proposed, such as intracoronary, intravenous, intramyocardial, retrograde 
sinus, and intrapericardial routes. None of the stem cell delivery routes has yet been 
proclaimed to be superior to the others and each one has individually shown some 
advantages. A vehicle that scientists have used in order to increase the efficacy of stem cell 
injections in regenerative medicine is injectable hydrogels. Alternatively, tissue engineering 
combines expertise in cell biology, engineering, and materials in order to grow a cardiac 
tissue in vitro. This tissue construct is engineered to mimic the behavior of human heart 
tissue and is later transplanted into a patient’s heart to improve or replace nonfunctional 
cells. Undifferentiated stem cells placed within cardiac constructs have been tested in MI 
animal models and have shown to improve survival rate, decrease the area of the damaged 
myocardium, and increase overall cardiac function. In these instances, stem cells 
differentiated into cardiomyocytes in vivo, and thus the differentiation process was 
uncontrolled and sometimes resulted in the development of teratomas. In further studies, 
scientists have differentiated stem cells in vitro prior to implantation of the cardiac construct, 
which offered improved results. Among the most successful methodologies in tissue 
engineering are the use of cell sheets and porous scaffolds. While neither regenerative 
medicine nor tissue engineering methods are sufficient as independent solutions for cardiac 
cell repair following MI, these approaches are advancing fast which demonstrates a strong 
potential for a stand-alone solution.
Recent advances are looking toward the refinement of current techniques and the 
minimization of complications. For example, the differentiation of stem cells into the right 
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cell lineage as well as the preservation of the genetic footprint are sometimes problematic 
and can be hindered by the development of teratomas.[6] Investigations have revealed that 
the source of stem cells is an important factor that affects cell differentiation. In addition, 
only a few of biomaterials used in regenerative medicine and tissue engineering have made it 
to human trials and improvements are necessary in terms of their mechanical, biological, and 
physical properties to provide optimal conditions for stem cell growth, differentiation, and 
retention.[7]
 2. Stem Cells to Heal Damaged Heart
Stem cells are undifferentiated cells that exist in various regions of the body and have two 
main roles. The first is growth for embryos and tissue maintenance and the second is 
regeneration and repair for adults.[3] There are several properties that stem cell types must 
exhibit in order to be selected as candidates for cardiac therapy. Primarily, they should be 
able to increase heart function by differentiating into cardiomyocytes when placed in a 
suitable environment and/or through indirect paracrine effects. The ability of stem cells to 
differentiate depends on their potency: pluripotent, multipotent, totipotent, or unipotent. The 
environment in which stem cells are cultured or delivered can facilitate the process of their 
differentiation into cardiomyocytes. Second, the cells must be relatively easy to isolate and 
maintain, and they should also have the ability to proliferate in sufficient numbers. In 
addition, they should be able to survive harvesting, delivery and the harsh microenvironment 
of the infarcted myocardium. Finally, stem cells should cause a low immunogenic response 
lest the benefits of the cells be completely annulled by the damage of an immunological 
response.[8]
Since cardiac tissue engineering and regenerative medicine requires a large quantity of cells, 
terminally differentiated adult cardiomyocytes which have a low proliferative capacity are 
unsuitable for these applications. Stem cells, on the other hand, can appropriately 
differentiate into cardiomyocytes and proliferate enough to meet the quantity requirements. 
Due to the relatively easy accessibility of resident stem cells, an ideal method would be to 
use cardiac-like cells derived from this type of stem cell.[9] The types of stem cells that have 
been used widely in animal models for cardiac repair are embryonic stem cells, induced 
pluripotent stem cells and stem cells from various adult tissues.[10]
 2.1. Types of Stem Cells
ESCs fulfill most of the requirements for stem cell based cardiac therapy including clonality, 
self-renewal and pluripotency.[3,10] ESCs have shown a clear ability to differentiate into 
functional cardiomyocytes and endothelial cells, therefore, they have the potential to 
reproduce several elements of damaged heart.[8] Cardiomyocytes derived from human ESCs 
have been tested on animal models and have been shown to survive after their 
transplantation, partly remodel the infarcted area, and positively improve contractile 
function.[11] Recently, researchers have been able to “reprogram” somatic cells to get them 
to an ES cell-like state by transduction of defined transcription factors.[3,12] These 
“engineered” ESCs called iPSCs have been shown to differentiate into functional 
cardiomyocytes.[13,14] The iPSCs present an appropriate alternative to human ESCs by 
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surpassing ESCs ethical concerns and providing an ideal autologous cell source, which 
reduces the chances of an immunological response.[5,15] Also, the use of iPSCs bypasses the 
need for invasive surgery because of the wide availability and accessibility of cells eligible 
for suitable reprogramming.[16] Although iPSCs have not yet reached a human trials phase, 
they have shown promising survival results in the infarcted myocardium and marginal 
renewal of heart function in animal models that are comparable to other cell sources. 
However, much work remains to be done in order to enhance their engraftment, survival rate, 
and therapeutic efficiency.[16]
Adult stem cells are another option that scientists have extensively studied. These cells are in 
several locations throughout the human body.[17] For cardiac purposes, scientists have used 
cells from several sources such as the heart, bone marrow, umbilical cord, placenta, and 
adipose tissue. For example, hematopoietic stem cells can be found in umbilical cords, 
placenta, and bone marrow.[3] MSCs can be harvested from femoral heads, endometrium, 
bone marrow and adipose tissue.[18] Due to their ease of accessibility through noninvasive 
surgery and their low immunogenicity, MSCs are good candidates for allogeneic stem cell 
therapies. In addition, they have a high proliferative potential and can be grown extensively 
in vitro, making them an attractive option for scientists.[17] Many studies on animal models 
have shown that the injection of MSCs is beneficial in the case of cardiac injuries and 
diseases.[19] The cells have been shown to differentiate into beating heart cells in vitro, to 
increase vascularization density when transplanted into ischemic murine model, and to 
prevent scar expansion.[20,21] MSC human therapy trials have recently started with initial 
success.[22] Among the different origins of MSCs, adipose-derived stem cells (ASCs) have 
shown great promise for an autologous source due to their large availability and relative ease 
of isolation through liposuction.[3,19] Around a decade ago, CSCs were found in the heart 
using negative c-kit,[23] Sca-1,[24] isl1[25] and cardiosphere-forming cells[26] stem cell 
markers. Since then, scientists have investigated their use in regenerative medicine using 
methods such as cardiosphere-forming technology to isolate CSCs from heart tissue. One 
example is the SCIPIO human trial that is being conducted with autologous c-kit+ CSCs for 
the treatment of MI. Results have revealed that the intracoronary delivery of these cells is 
safe, improves LV systolic function and reduces the size of the ischemic tissue. However, 
surviving and engrafted cells are low in number.[27,28] Along with CSCs, another important 
adult cell type that needs to be considered is endothelial progenitor cells (EPCs). These cells 
are defined as circulating cells that express a variety of cell surface markers similar to those 
expressed by vascular endothelial cells, adhere to endothelium at sites of hypoxia/ischemia, 
mediate tissue-protective effects, and participate in new vessel formation.[29] In an 
experimentally induced MI, neoangiogenesis triggered by EPCs resulted in decreased 
apoptosis of hypertrophic myocytes in the peri-infarct region, longterm salvage and survival 
of viable myocardium, reduction in collagen deposition, and sustained improvement in 
cardiac function.[30]
Each of the sources of cells previously mentioned have their own drawbacks that scientists 
are striving to overcome. CSCs and EPCs do not pose an ideal solution due to their 
scarcity.[31] Isolation of adult stem cells remains a problem since it usually results in a 
heterogeneous population of cells, which requires the use of cell surface markers to isolate 
the required stem cell types. The use of ESCs is significantly hindered by ethical issues as 
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well as risks of teratoma formation.[12,32] Also, more research needs to be conducted to 
study iPSC behavior in order to minimize the possibility of teratoma formation and optimize 
therapeutic benefit in damaged myocardium. Scientists are working hard to resolve these 
issues to determine the ideal source for cardiac tissue engineering and regenerative 
medicine. Many studies are being conducted to better define the intrinsic nature of the adult 
stem cell types mentioned above as well as the mechanism behind some of the noted 
differentiation, transdifferentiation and engraftment contributing to the improvement of 
cardiac function. Despite the fact that stem cell grafting and retention has remained low, 
results look promising.
 2.2. Regenerative Medicine Cell Delivery Routes
Regenerative medicine induces myocardial repair at the site of injury in vivo and prevents 
ventricular dilatation after MI through an injection of stem cells. Successful delivery is 
crucial for an ideal stem cell therapy into the cardiac tissue. There are five main delivery 
routes: intracoronary, intravenous, intramyocardial, retrograde sinus and intrapericardial.[33] 
The intracoronary infusion technique involves cell fusion through the central lumen of a 
balloon catheter positioned in the coronary artery.[34] This route limits risks of systemic 
administration, as the delivery concentration is higher in ischemic and border zone regions. 
It is generally used for patients who have electrocardiographic ST segment elevation MI or 
patients with chronic myocardial ischemia.[35] The simplest delivery route is intravenous 
delivery. It has the advantage of being noninvasive and is often referred to as one of the 
safest delivery methods.[36] It is usually done through a peripheral or central venous 
catheter.[37] However, a high number of exposed cells may end up in other organs and only a 
small amount will reach the target area, which reduces the efficiency of this technique.[38–40] 
Furthermore, patients with occluded arteries usually cannot benefit from an intravenous 
injection. Another method is the intramyocardial injection. This delivery method consists of 
the direct injection of stem cells into the myocardium via a transepicardial or 
transendocardial injection. It is generally used for patients with an ischemic cardiomyopathy. 
The exact location of the infarcted tissue can be identified using echocardiography or 
nuclear imaging.[41] Transepicardial injection is performed using a needle-syringe while 
directly visualizing the heart.[42] However, the operation is risky due to the need for open-
heart surgery.[43] The transendocardial approach does not require surgery, but it provides less 
visibility because it is performed in a percutaneous way.[44] Catheters are passed from 
peripheral vessels into the left ventricular cavity.[42] Electromechanical mapping systems 
can be used to increase visibility during the procedure. The drawbacks of both techniques 
include increased risks of perforation, embolization and cardiac arrhythmias.[45] The 
retrograde coronary sinus delivery consists of placing a balloon infusion catheter after 
catheter placement into the coronary sinus. The balloon is then inflated and cells are 
delivered at pressures of 50–60 mm Hg maximum, which are higher than the coronary sinus 
pressure.[46] This emerging technique may be efficacious and is considered safe.[47] Recent 
studies have shown that injection using this method delivers cells with a better homogeneity 
across the heart.[48] The last injection method is the intrapericardial injection. One of its 
advantages is a relatively high number of deposited cells. However, the movement of cells 
across the visceral pericardium is essential. Little is known about the efficiency of this 
technique, as it is the least researched. To date, there is no specific route that has been 
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proclaimed to be the finest technique for cellular therapy. Table 1 summarizes the prospects 
and challenges of different cell delivery strategies to maximize the stem cell based 
therapeutic strategies for cardiac tissue repair and regeneration.
 3. Mode of Therapeutic Actions: Knowledge So Far
There have been several studies that show positive remodeling of damaged myocardium 
after stem cell therapy. However, some ambiguity still remains on the mechanisms of 
engraftment of stem cells and their subsequent beneficial effects to the ischemic cardiac 
zone. The original theory that scientists proposed was that the stem cells delivered to the 
myocardium differentiate into new cardiomyocytes to produce the positive remodeling of the 
damaged tissue. However, due to scientific evidence that will be discussed in the following 
section, several scientists now believe that paracrine signaling between the delivered stem 
cells and resident stem cells are responsible for those effects.
 3.1. Paracrine Signaling
Extracellular growth factors, cytokines and ligands constitute parts of signaling pathways at 
the center of cardiomyocyte differentiation, development, growth, function and metabolism. 
Low engrafted cell survival and proliferation with a relatively high outcome in regeneration 
suggests the involvement of paracrine factors secreted by the implanted cells. Stem cell 
homing factors such as growth factors, chemokines and cytokines are believed to improve 
cardiac function through neovascularization, angiogenesis, decreased apoptosis, decreased 
fibrosis, increased cell proliferation, as well as stem cell mobilization, differentiation and 
migration to the infarct zone. Significant effort is being put toward both understanding the 
mechanisms by which these biological molecules produce these positive results as well as 
delivering these molecules using different techniques. These investigations are indicating 
that these biological molecules could potentially be used in regenerative medicine and tissue 
engineering to aid stem cells grafting and retention in the heart.
Cytokines play an important role in cell differentiation, proliferation and apoptosis. They 
constitute a wide range of proteins that are involved in the communication and interactions 
between cells. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are cytokines 
that are released shortly after acute MI.[31] The sustained presence of cytokines leads to the 
modification in myocyte phenotype and activation of matrix metalloproteinases, which 
modifies the interstitial matrix and further augments the remodeling processes.[31] Cytokines 
have the ability to trigger not only beneficial pathways to cellular regeneration such as 
restoration of function and angiogenesis, but also detrimental pathways such as apoptosis, 
chronic dilatation and stroke.[49] Chemokines are chemotactic cytokines that play an 
important role in several processes, including angiogenesis.[50,51] A stem cell homing factor 
that has recently received considerable attention is the stromal-derived factor (SDF)-1-α.[52] 
This chemokine has been shown to increase transcoronary migration and homing of stem 
cells to the ischemic myocardium,[53,54] angiogenesis, cell survival,[52,55] and improve 
ventricular function.[56] Recent research has shown that these positive results are due to the 
local release of SDF-1-α by MSCs that leads to the recruitment of CXCR4+ cardiac 
progenitor cells.[57] Upon the SDF-1-α:CXCR4 binding an antiapoptotic effect mediated by 
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the phosphoinositide 3-kinase/Akt signaling pathway was shown. Lastly, the signaling 
associated with this pathway was shown to not cause cardiomyocyte hypertrophy, therefore, 
eliminating hypertrophy as a cause of positive cardiac remodeling.
In order to increase the efficacy of these paracrine factors and to take advantage of other 
delivery routes, scientists have recently explored delivery systems such as 
microparticles.[58,59] These microparticles overcome several drawbacks associated with 
direct injection of the paracrine factors including protein instability and short circulation 
protein half-life after injection. Specifically, the PLGA microparticles used by Formiga et al. 
were shown to provide sustained delivery of VEGF165 for more than one month and to 
increase angiogenesis and arteriogenesis. On the other hand, the VEGF solution and empty 
microparticles did not show these results after one month. Using particles to increase the 
clinical viability of paracrine factors shows great potential for cardiac regeneration. 
However, degradation, size, protein half-life, and release kinetics are all important factors 
that need to be carefully considered when deciding on a delivery technique.
Although researchers have some cues for reaching effective stem cell therapies for the 
regeneration of the heart, there are still many unknown mechanisms that are currently under 
investigation. Concentration on the synergistic effects of growth factors, cytokines and 
adequate stem cells reveal complex questions but promising results.
 3.2. Differentiation of Stem Cells
Several scientists are studying ways to differentiate stem cells into cardiomyocytes. 
Successful methods are characterized by the expression of the correct genetic footprints and 
prevention of tumor cell development. Various techniques are being developed to ensure that 
the correct genetic footprint is maintained. One example is seeding the cells on scaffolds, 
which is expected to prevent the loss of genetic markers of differentiated cardiomyocytes 
especially after implantation into the host cardiac tissue.[60] Furthermore, it is important that 
the developed methods be scalable to allow the transition from experimental to clinical 
applications.[61]
One source of stem cells that has shown capability to be differentiated into cardiac muscle 
lineages is bone marrow.[62] Bone marrow stem cells have been applied to various 
applications such as cardiac patch tissue engineering.[20] According to Fukuda et al., mouse 
bone-marrow stem cells differentiated into a cardiac cell line demonstrate cardiomyocyte 
genes. In addition, spontaneous beating and pacemaker characteristics that mimic native 
ventricular-myocyte and sinus-node functions have also been noted. Nevertheless, this cell 
source also presents some challenges, such as the tendency to differentiate into bone and 
cartilage cells. Another significant problem seen with this cell line is that the delivered 
action potentials have smaller values than those found in native human myocardium.
Several factors have been found to affect the differentiation of stem cells into 
cardiomyocytes. The source of the stem cells greatly affects the lineage they will 
differentiate into, as revealed by Tompkins et al. through their discussion on stem cell 
“memories”.[60] For example, human cardiomyocytes differentiated from cardiac derived 
iPSCs were more easily obtained than those differentiated from fibroblast derived iPSCs. 
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Scientists have also found success deriving cardiac cells from bone marrow derived 
MSCs.[63] Another factor that can also affect the differentiation of stem cells from various 
sources into cardiomyocytes is the addition of external molecules. Inhibitors can also be 
used to promote differentiation into cardiac cell lineage. For instance, the inhibitor 
trichostatin A has been shown to promote embryonic stem cell differentiation into 
cardiomyocytes and to increase the physical maturation of these cells.[60]
However, the differentiation of stem cells into cardiomyocytes has also resulted in teratoma 
development. The source of the developed cancer cells is mainly the stem cells that remain 
in their undifferentiated state in the culture. Several methods have been proposed to remove 
undifferentiated stem cells and prevent cancer cell growth in the differentiated 
cardiomyocytes.[64] Differentiated cardiomyocytes can be identified and separated from 
undifferentiated stem cells or those that have differentiated into other lineages by flow 
cytometry, micro-dissection, genetic selection, and buoyancy measurements.[60] However, 
some of these strategies themselves induce mutations and teratomas in the cell cultures. 
Therefore, future work needs to be done on how to negate this teratoma formation in order 
for stem cell therapy to become a viable widespread treatment option.
 4. Boosting Stem Cell Therapy with Engineered Biomaterials
Different methodologies have been used to deliver stem cells to damaged myocardium 
including cell sheets, injectable hydrogels, porous scaffolds, cell-surface engineering, and 
microcapsules. Both natural and synthetic polymers have been used to make such delivery 
devices with each type of material providing its own benefits and challenges. This section 
will focus on the current research reported using each of these methods. Also, the current 
challenges of each method will be discussed along with strategies scientists are using to 
overcome these challenges to produce the best therapeutic benefit.
Natural polymers have several properties that make them ideal for tissue engineering and 
regenerative medicine. One of the most notable and unique characteristics is their bioactivity 
through providing signals to cells. Examples of natural polymers used in cardiac tissue 
engineering are collagen,[65] gelatin,[66] hyaluronan,[67] fibrin,[68] chitosan,[69] alginate[70] 
and Matrigel.[71] Fibrin, collagen I, and Matrigel, are commercially purchased polymers that 
can be used as hydrogels in cardiac patch tissue engineering with results showing improved 
cardiac function as well as increased vascularization of the grafted tissues.[72] One study 
discovered that human ESCs seeded on fibrin-based matrices formed highly functionalized 
cardiac tissues and improved results were seen in 3D gels compared to 2D gels. The 
properties compared were sarcomere length and presence of certain genes for cardiac 
contractility.[73] Natural polymers can also be used for an electrospun scaffold, as seen when 
a hemoglobin/gelatin/fibrinogen (Hb/gel/fib) nanofiberous construct was used to study MSC 
differentiation into cardiomyocytes.[74] Immunocytochemical assays for cardiac marker 
protein actinin showed that the MSCs did indeed begin to differentiate toward a 
cardiomyocyte lineage. The cells also began to exhibit morphological characteristics 
indicative of cardiomyocytes. However, in general, natural polymers suffer from poor 
mechanical properties and are prone to generating immune response from the host.[75] 
Hasan et al. Page 9













Nevertheless, if these mechanical problems can be overcome, the bioactivity of the natural 
polymers can prove to be a valuable tool in controlling stem cell behavior.
Alternatively, synthetic polymers are attractive because of the substantial control scientists 
have over tailoring their physical and chemical properties. Several hydrogels are currently 
being developed to mimic cardiac tissue properties and characteristics.[76] Elastomeric 
hydrogels, for example, have high elastic and tensile strength properties, which are needed 
in the tough myocardial environment.[77] Enhanced biomimetic properties are also seen in 
conductive hydrogels. These hydrogels have an improved ability to conduct electric signals 
and therefore, assist in maintaining a constant synchronization of the beating rates for 
grafted and native cardiac tissues. Scientist have also used separate synthetic polymers to 
create a composite scaffold using two different techniques in order to better mimic the native 
extracellular matrix.[78] Specifically, Xu et al. used electrospun polyurethane fibers in 
combination with a hydrogel based on N-isopropylacrylamide (NIPAAM), acrylic acid 
(AAc), 2-hydroxyethyl methacrylate (HEMA), and oligo (β-butyrolactone). They modulated 
several composition characteristics including global moduli, single-fiber moduli, fiber 
alignment and density. The bioactivity of these scaffolds was tested by electrospraying 
cardiosphere-derived cells and monitoring their differentiation toward cardiomyocytes. The 
results showed that although the cells attached to each scaffold composition relatively 
equally, the RT-PCR cardiac differentiation was enhanced with the lower scaffold modulus 
and highest fiber diameter as seen in Figure 1C. This study further confirms that finding the 
optimal composition and mechanical properties of scaffolds is important in order for stem 
cell therapy to reach therapeutic efficacy. Despite the fact that the mechanical properties of 
synthetic hydrogels can be relatively easy to tailor, their lack of bioactivity has proven to be 
a significant problem that scientists are continuing to work toward overcoming.
 4.1. Cell Sheets
The “Cell Sheet Engineering” approach to tissue engineering utilizes stacks of many 
individually harvested thin tissue layers to fabricate an integrated functional tissue in 
vitro.[79] In its early stages, this approach presented a “backward” technique due to the 
enzymatic harvesting steps that destroyed the engineered cells.[80] However, recent advances 
in scaffold coating strategies have allowed the easy detachment of cultured tissues from their 
“smart” scaffolds, keeping any developed cell-surface proteins and extracellular matrix 
connections intact.[80] The resulting stacked cell sheets resemble dense native cardiac tissue, 
and can be implanted without sutures through open heart surgery resulting in long-term 
survival and growth rate.[79,81] As a result, the cell sheet approach has become one of the 
most promising techniques in cardiac tissue engineering.[82] In fact, transplants of stacked 
cell sheets prepared from skeletal myoblasts into infarcted myocardium in MI rat models 
have shown positive results concerning vascularization and proliferation of healthy cardiac 
cells in the damaged areas.[83] Cell sheets derived from muscle stem cells have also been 
shown to yield better functional recovery in chronic infarcted myocardium than cell 
injections have.[84] As shown in Figure 1A, the cell sheets had a significant increase in cell 
survival, which then translated into a better therapeutic outcome in the form of reduced scar 
fractional area and increased formation of fast-skeletal myosin heavy chain positive 
myofibers. Bursac et al. discusses the high potential of cell sheets seeded with adipose 
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derived MSCs, which after implantation into infarcted myocardium in rat models increases 
the myocardium wall thickness.[83]
Scientists use thermoresponsive coatings for the growing scaffold, which results in the 
successful growth of cardiac tissue in vitro for several reasons. First, each cardiomyocyte 
sheet consists of electrically and chemically coupled cells and can therefore maintain a 
synchronized pulsation.[81] In addition, although cell sheets initially lose pulsation after 
being stacked, synchronized beating is eventually restored and can be seen in macroscopic 
view.[81] Finally, the engineered graft area increases with host size after implantation, 
accompanied by an increase in conduction velocity and force. This is seen in implants of 
stacked myocardial layers in rats over a period of 24 weeks.[79] The most common 
thermoresponsive material used in the tissue engineering of cell sheets is poly(N-
isopropylacrylamide) (PNIPAAm), which has a low critical solution temperature (LCST) of 
32 °C.[80] This implies that the polymer is hydrophobic at temperatures above 32 °C, which 
encourages cell adhesion, and hydrophilic at temperatures below 32 °C, which encourages 
cell detachment.[79] These characteristics make the polymer ideal for tissue engineering 
applications; cells can be cultured on the PNIPAAm polymer at their nominal growth 
temperature of 37 °C and then safely harvested at a temperature below the LCST without 
damaging the cell-to-cell junctions or the extracellular matrix found between the harvested 
cells.[82] Another recent study showed that ASC cell survival in an ischemic heart can be 
increased by using thermoresponsive cell sheets.[85] These cell sheets were shown to 
improve ejection fraction as well as develop a new vascular network. Another example is the 
use of human amniotic fluid stem cells which have shown positive results when seeded on 
collagen hydrogels coated with temperature responsive material, such as methylcellulose 
hydrogels.[86] Transplantation of the obtained cell sheets increased the left ventricle size in 
infarcted rat models within four weeks.[86] Improved engraftment was also seen due to the 
increased extracellular matrix obtained from the cell sheet method.[86]
 4.2. Injectable Hydrogels
Hydrogels are 3D networks of polymers that share several characteristics with natural extra-
cellular environments.[77] They are hydrophilic and swell when exposed to water, and they 
can also promote the growth and adhesion of cardiovascular cells. Tissue engineering of 
cardiac tissue based on injectable hydrogels begins with encapsulating the cells.[87] This is 
achieved by mixing the cells and the matrix solution before incubating the solution for 
gelation.[81,87] The resulting gel is a homogeneous mixture consisting of cells, extracellular 
matrix proteins, and polymer. The gel is directly injected into the desired host cardiac tissue 
as a liquid and then polymerizes in the host tissue, becoming fixed.[81] The complete 
biodegradation of all polymer residues has been reported within six weeks after injection. 
Hydrogels have been reported to enhance stem cell retention and survival upon their 
injection into animal heart models.[88] Also, hydrogels provide an environment for cells 
where scientists can control the mechanical properties and, therefore, enhance stem cell 
differentiation. Li et al. encapsulated MSCs in a thermosensitive hydrogel made of N-
isopropylacrylamide, N-acryloxysuccinimide, acrylic acid and poly(trimethylene carbonate)-
hydroxyethyl methacrylate.[89] These hydrogels had varying moduli due to varying 
concentrations of the polymers used. The results showed that the cells encapsulated in the 
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hydrogel with the highest modulus had a greater increase in MSCs differentiation to 
cardiomyocytes as seen in Figure 1B. Hydrogels that have been injected with hESC vascular 
cells show improved vascularization of infarcted heart areas in rat models and maintain 
myocardium contractile rates.[90] This has also been correlated with a decrease in area of the 
damaged site, viewed using magnetic resonance imaging techniques.[90] Due to their relative 
ease of delivery and tunable properties, injectable hydrogels hold a great promise for 
enhancing the efficacy of stem cell therapy to the heart.
 4.3. Porous Scaffolds
Porous scaffolds are distinguished from hydrogels by their interconnected pores that allow 
the seeded cells to travel, proliferate, communicate, and form extracellular matrix 
components throughout the entire scaffold.[91] These pores also permit diffusion of nutrients 
and metabolic wastes. Pores are essential to cardiac tissue scaffolds as they increase 
vascularization, especially when combined with medium perfusion techniques that can 
enhance cardiac cell motion through the scaffold.[92] Scaffolds can be made porous through 
various techniques, depending on the material being used and the pore characteristics.[93] 
These techniques include freeze drying,[94] leaching,[95] 3D printing,[96] electrospinning,[97] 
and fiber extrusion.[98]
Scaffolds from natural and synthetic materials can be used in cardiac tissue engineering, 
although some have been shown to be more receptive to cardiac cell seeding than others.[99] 
According to Herrmann et al., polyurethane is identified as being among the best in the 
context of myocardial tissue engineering.[99] Fromstein et al. revealed the effect of different 
scaffold architectures on the development of cardiac patches from cardiomyocytes derived 
from embryonic stem cells.[100] Polyurethane scaffolds having different “macro-
architectures” were fabricated using electrospinning or thermally induced phase separation 
(TIPS) techniques. Although both fabrication methods resulted in patches with contracting 
cells, only the stem cells seeded on the fibrous meshes from the electrospinning technique 
developed into the typical elongated morphology seen in cardiomyocytes derived from 
ESCs. Rai et al. developed a biomimetic PGS hydrogel sequentially treated with alkaline 
hydrolysis and acid and reported homogenous immobilization of the fibronectin and laminin 
peptide sequence.[101] It was shown that the porous PGS scaffold is biocompatible with rat 
CPCs and human cardiac MSCs. These results hold promise for PGS to serve as 
biomaterials for carriers of cells into the heart for cardiac tissue engineering. Ravichandran 
et al. discusses several comparable mechanical properties between PGS, fibrinogen core, 
shell scaffolds and native myocardial tissues.[102] Similarly, Prabhakaran et al. studied the 
embryonic stem cell behavior on a poly(d,l-lactide-co-glycolide)/collagen (PLGA/Col) 
scaffold versus a pure PLGA scaffold.[103] They found that the PLGA scaffold exhibited 
much higher tensile strength properties. However, the PLGA/Col scaffold proved to better 
support the interaction and growth of ESC differentiated cardiomyocytes. This highlights the 
importance of combining natural and synthetic polymers in the production of porous 
scaffolds in order to obtain a scaffold that can facilitate cell adhesion and provides ideal 
mechanical properties for cardiac tissue engineering.[93]
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 4.4. Cell-Surface Engineering with Bioactive Molecules
As mentioned previously, stem cells have the potential to regenerate tissue damaged by 
several cardiovascular diseases including myocardial infarction. However, to date, cell 
therapy has not reached the efficacy level needed and requires invasive surgeries to deliver 
cells to the target location. Ideally, a systemic infusion should be used, but only 
approximately 1% of the cells have been shown to home to the tissue of interest.[104] In 
addition, regardless of which delivery technique is used, scientists have observed that less 
than 10% of the injected stem cells are present in the heart 24 h following treatment.[105,106] 
Therefore, scientists have begun modifying the surface of stem cells in order to promote cell 
homing and engraftment at the treatment site. This can be accomplished by stimulating 
interactions between the stem cells and the endothelium typically used by hematopoietic 
stem cells and leukocytes that MSCs inherently lack.[104,107,108] These interactions lead to 
initial rolling and subsequent adhesion that results in transendothelial migration into the 
tissue. Specifically, Sarkar et al. used glycoprotein ligand-1 of the P-selectin active site 
called sialyl Lewis X (SLeX).[104] They attached a SLeX to MSCs using a biotin–
streptavidin bridge after a lipid vesicle had been attached to the cell membrane using 
biontinylation. A schematic representation of the synthesis can be seen in Figure 2A. Their 
results showed that under shear stress the modified cells had a greater percentage of cells 
interacting with a P-selectin coated surface through both adhesion and rolling mechanisms. 
Although this method proved to be effective, streptavidin may cause an immune response 
and a method with less steps is more ideal. Cheng et al. used a simple procedure to 
chemically modified the MSC membrane using NHS-PEG2-maleimide as a membrane 
bound linker molecule and cysteine to provide the N-terminus thiol needed to react with 
maleimide.[107] After attaching a known strong binding peptide to the MSCs using this 
method it was shown that the cells targeted and adhered to E-selectin in an in vitro model of 
an inflamed blood vessel under physiological shear stress. In addition, this group proved that 
the binding kinetics of the peptide–selectin interaction can be modified in order to promote 
the MSCs to roll under physiological shear stress. To accomplish this they used a peptide 
that had a moderate binding IC50 with E-selectin to modify the stem cell membrane. This 
discovery is particularly important for the field because it validates theoretical models that 
had previously only been used to explain natural cell or bead rolling. This allows scientists 
in the future to refine theoretical models in order to develop better engineered cells for the 
purpose of targeting damaged tissue like damaged myocardium. It is important to note that 
both studies confirmed interactions were observed while the MSCs maintained their 
viability, proliferation, and differentiation ability. These studies prove that by modifying the 
surface of stem cells in accordance with specific ligands expressed by the target cell type, 
scientists have the ability to promote interactions leading to stem cell homing after systemic 
injection and increased retention regardless of which delivery route is chosen. Targeting the 
specified adhesion molecules mentioned above holds great promise for tissue regeneration 
due to the fact that both E and P-selections are overexpressed by inflammatory cytokine-
activated endothelial cells present in damaged tissue including damaged myocardium. 
Recently, Chi et al. reported a pilot study in which they tested this theory using a porcine 
ischemia-reperfusion model.[105] Results showed that by incorporating a P-selectin 
glycoprotein ligand-1 mimetic onto the surface of cardiosphere-derived cells they were able 
to detect 28% of the cell population in the left anterior descending coronary artery region 3 h 
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after injection. Although this study confirms the feasibility of using selectin-ligand 
functionalized cardiosphere-derived cells for targeted regeneration of damaged myocardium, 
future tests should be aimed at investigating the retention of the cells in the target region at 
longer time points in larger in vivo studies.
 4.5. Polymeric Microcapsules
Although stem cell injections directly into the myocardium have been shown to promote 
positive remodeling of the tissue, the problem of cell retention still remains. Once injected, 
scientists have found that the contractile nature of the myocardium flushes the stem cells 
away from the site.[109] One method being studied in order to overcome these problems is 
the use of microcapsules as delivery systems for stem cells. As mentioned with the previous 
methods, a major benefit of using a polymeric delivery method such as microcapsules is that 
the mechanical and biological properties of the microcapsules can be manipulated based on 
polymer composition to influence stem cell behavior. However, due to the relatively small 
size of microcapsules, there are rarely concerns regarding adequate transport of oxygen and 
nutrient to the cells that other hydrogel techniques might encounter.[110] Several polymers 
have been used for such microcapsules, including extracellular matrix proteins,[111] 
PLGA,[112] alginate,[113] fibrinogen,[114] and chitosan[115] among several others. 
Specifically, Paul et al. recently used alginate microcapsules to encapsulate genetically 
modified human adipose-derived stem cells.[113] They used recombinant baculovirus and 
PAMAM dendrimers to transduce the cells with a gene to cause the overexpression of 
VEGF. As reported in Figure 2B, due to this overexpression of VEGF when the cells were 
injected into a rat model, significant positive remodeling was observed over a 10 week 
period in the form of increased injection fraction, fractional shortening, angiogenesis and 
arteriogenesis. Recently, Blocki et al. developed a composite microcapsule for the 
encapsulation and delivery of MSCs to the myocardium post myocardial infarction.[111] The 
biomaterials used for the microcapsule production were agarose, collagen I, fibrin, and 
dextran sulfate. The slow degradation profile of agarose allows for cells to be released into 
the damaged tissue in a controlled manner while the extracellular matrix proteins and 
dextran sulfate were chosen due to their ability to positively impact cell behavior. More 
specifically, the presence of dextran sulfate caused extensive cell spreading, proliferation and 
survival within the microcapsules. Following their material optimization, in vivo tests were 
carried out in a rat model where the microcapsules containing MSCs labeled with TAT 
peptide derivatized ultrasmall superparamagnetic iron oxide nanoparticles were injected into 
the peri-infarct and infarct region of the heart. A magnetic resonance signal indicating the 
presence of labeled MSCs could be detected up to 6 weeks in the groups that received the 
microencapsulated MSCs. However, at most, a weak signal was detected early in the group 
that received a single cell suspension. These results indicate that the microencapsulation of 
the MSCs did increase the cell retention in the damaged myocardium. Future studies 
assessing cardiac function post treatment would be beneficial in order to fully assess the 
therapeutic benefit of this treatment. Instead of using some of the natural polymers 
mentioned above, Lee et al. used PLGA in combination with polyethylenimine (PEI1.8k) in 
order to encapsulate MSCs in porous microcapsules.[112] PLGA was chosen due to its ideal 
degradation profile and PEI1.8k was added in order to enhance cellular retention due to 
electrostatic interactions. In vivo results showed that after injection into the damaged 
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myocardium all three micro-encapsulated cell groups had a greater engraftment rate 2 weeks 
after treatment. However, as stated previously, further in vivo test should be performed in the 
future to assess how the cardiac function is affected by these positive results. In addition, in 
vivo testing over a longer time period, as seen in the previous examples, is needed to make 
an accurate assessment of the therapeutic potential of the treatment. These examples along 
with other studies provide evidence that microcapsules offer scientists with a viable method 
for enhancing stem cell therapy by providing a tunable delivery system.
 5. Role of External Mechanical Stimuli on Cardiac Differentiation
Stem cells are unique in the fact that they differentiate based on the biological and 
mechanical cues they receive from their environment. Scientists have used this trait to their 
advantage by seeding cells on substrates with specific mechanical properties, and also by 
subjecting the cell seeded substrates to mechanical stimulation. For a tissue engineering 
approach, scientists use bioreactors as an attempt to improve the engineered cardiac tissue 
by driving it to mimic native cardiac muscle behavior.[116] Subjecting stem cells to 
biomimetic signals also improves cardiac gene expression in differentiated stem cells.
When designing a device for stem cell delivery, the fabrication method and material 
properties can greatly influence the stem cell fate.[117] This is called mechanotransduction, 
and is when the mechanical properties of the material evoke a physical stimulus that 
translates into a biological response in the cells. Scientists have used this to their advantage 
when choosing the materials to use for stem cell delivery devices. For example, Williams et 
al. studied how the modulus of hydrogels with different compositions of ECM and fibrin 
affected the behavior of C-kit+ progenitor cells.[118] As seen in Figure 3A, as the moduli of 
the substrate increased the cardiovascular gene expression increased as well. This indicates 
that stiffer substrates provoke this type of progenitor cell to differentiate toward a cardiac 
lineage. Another example of stem cell fate dictated by substrate properties can be seen in the 
study by Sreerekha et al., where scientists observed how the diameter of electrospun PLGA 
and PLGA-fibrin fibers influenced MSC behavior.[119] This study proved that a composite 
scaffold with fibrin nanofibers ranging from 50 to 300 nm and PLGA microfibers ranging 
from 2 to 4 µm enhanced MSC differentiation into cardiomyocytes and proliferation. This 
provides evidence that a substrate with a heterogeneous network of fibers provides a more 
ideal environment for cardiomyocytes to thrive.
Another method for influencing stem cell fate is subjecting the cells to mechanical 
stimulation using a bioreactor. The first type of bioreactor was used to mimic the physical 
and mechanical stimulations found in the environment of native cardiac muscles.[120] This 
conditioning increases the force of contraction generated in rat cardiac constructs revealing 
the importance of mechanical bioreactors in engineering biomimetic cardiac 
muscles.[116,121] Mechanical simulation of engineered cardiac tissues has also been shown 
to enhance cardiomyocyte proliferation.[121] In fact, elastic properties have been improved 
by seeding mouse embryonic stem cells onto poly(lactide-co-caprolactone) scaffolds and 
stimulating the scaffold using cyclic stretch bioreactors.[90] Guo et al. demonstrated that 
stretching cardiac patches fabricated from differentiated ESCs also results in synchronous 
beating and response to environmental changes.[122] Proper stimulation of stem cells is a 
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vital step in the development of cardiac patches because their differentiation into a certain 
cell line is determined by the signals they are subjected to.[83] For example, imposing a 2 Hz 
cyclic stretch over a period of 7 d was shown to prevent tumor development in cardiac 
patches developed from embryonic stem cells.[83] Another example was shown by observing 
the effect of static strain on a MSC seeded electrospun poly(ester carbonate urethane) 
scaffold.[123] The electrospinning technique allowed scientists to fabricate a scaffold that 
mimicked the anisotropic and biaxial mechanical properties of native porcine myocardium. 
As shown in Figure 3B, the magnitude of static strain greatly affected both the cell 
morphology and differentiation. The anisotropic index of the tissue construct without static 
stain was 0.14. However, after applying a 75% static strain the anisotropic index changed to 
3.28 and the difference in cellular alignment can clearly be visualized in the Figure. Even 
more intriguing is the dramatic upregulation of key early cardiac differentiation genes 
GATA4 and Nkx2.5 that was detected. When compared to the MSCs cultured on standard 
tissue plates, the 75% strained tissue constructs exhibited approximately a 4000 and 600 fold 
increase of GATA4 and Nkx2.5 expression, respectively. These results clearly demonstrate 
the immense potential of using mechanical stimulation to engineer a tissue construct that 
mimics both the mechanical and cellular properties of the myocardium. Current bioreactors 
are sophisticated, large, unreliable, and difficult to operate and maintain.[121] This prevents 
their use in the mass-production of cardiac patches and limits them to experimental 
applications. Nevertheless, recent advances in bioreactor technologies have allowed the 
recreation of the native cardiac environment in the lab by providing the needed mechanical, 
biochemical and electrical signals.[9] In addition, the emergence of several prototypes for 
portable micro-bioreactors[124] with minimal pumps, valves, and accessories[125] improves 
the potential of tissue engineering to eventually meet the clinical need and mass production 
of cardiac patches.[126] Biochemical stimulation can also be used. Bioreactors within this 
category are denoted by “spatial control” reactors, since they are used to deliver growth 
factors and molecules in specific amounts within the required cells only.[127] Biochemical 
stimulation enhances the vascularization of cardiac patches engineered from rat models, 
which increases the amount of oxygen supplied to the cardiomyocytes to the required level 
found in native tissues.[116]
Lastly, cardiac patches are subjected to electrical bioreactors. Electrical stimulation of 
engineered cardiac tissue aligns cardiomyocytes seeded onto scaffolds.[121] In addition, it 
enhances the electrical conductivity properties of the engineered cardiac muscle by 
increasing the electrical coupling between the cells, which increases the conduction velocity 
and establishes a rate comparable to that of native cardiac tissues.[121] This has been shown 
through several experiments performed on rat and mouse cardiac patch models which 
highlights the ability to engineer “pacemaker” cardiomyocytes.[9,121]
Cyclic stretching, stretching, Percoll gradient centrifugation, and electric field stimulation 
are some of the common bioreactors and stimulation techniques used in preparing cardiac 
patches from various stem cell sources.[83,122] These techniques can also be helpful in stem 
cell proliferation and expansion in vitro.[122] Some of the most important types of 
bioreactors are outlined in Table 2, along with their potential applications and benefits. 
Although there are significant obstacles associated with the use of bioreactors as mentioned 
above, this technology provides a valuable tool for scientists to engineer more sophisticated 
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cardiac patches in vitro prior to implantation. This has the potential for these types of 
devices to have a reduced risk of failure when transplanted into the human body.
 6. Implementing Microscale Techniques for Cardiac Tissue Engineering
Cardiac cell engraftment and retention has remained variably low after transplantation of 
tissue constructs into the heart. One main reason is the insufficient flow of oxygen and 
nutrients that is required through an intricate micro-vessel network. The formation of this 
network is currently slow, resulting in dying cells because of the lack of blood vessels in the 
proximity. Microfluidics offers some remedies for this problem in the area of tissue 
engineering by enabling scientists to control the spatial distribution of cells and the chemical 
gradients. Scientists can also induce flow signaling and transduction, thereby achieving high 
precision in the reproduction of the cardiac in vivo microenvironment.[128] This section will 
focus on different methods in which scientists are creating vascular networks using 
microfluidics for cardiac tissue engineering.
In cardiac tissue engineering, vascularization is a crucial element for cell survival and 
improvement of cardiac function. Prevascularization and angiogenesis/vasculogenesis are 
two methods that are used to construct vessel networks. Prevascularization aims at 
constructing branched perfusable blood vessel networks in the cardiac cell tissue prior to 
implantation. The vessel network is designed such that anastomosis occurs instantly upon 
implantation. With this prevascularization technique researchers have gained a precise 
control over the spatial arrangement of the vessel network. Microfluidics offers a number of 
techniques for the in vitro formation of vessel networks which can be grouped under (1) 
subtractive methods (needle-based molding method or dissolvable network-based sacrificial 
molding[129]), (2) additive methods (bonding of preformed hydrogel slabs) and (3) hybrid 
methods (bioprinting).[130] Continuous delivery of oxygen and nutrients, continuous removal 
of metabolic wastes, high rate of vascular anastomosis, immediate perfusion, and maturation 
upon implantation are major advantages of prevascularization. In vasculogenesis and 
angiogenesis, the scaffold is prepared in vitro using techniques that enhance blood vessel 
formation in vivo. Preparation techniques for vessel formation using microfluidics 
technologies include (1) micropatterning, (2) use of functionalized biomaterials, (3) 
induction of gradient of growth factors and (4) control of cell to cell interactions using co-
culture of multiple cell types.[129,130] Micropatterning can also be used to guide the 
proliferation and alignment of stem cells in order to create a more functional tissue.[131] For 
example, Giridharan et al. cultured embryonic cardiomyoblasts on a thin poly-dimethyl-
siloxane (PDMS) synthetic polymer membrane in a device modeling the left ventricle 
resulting in a construct that succeeded in simulating diastolic loading.[132] Tsang et al. 
proved this concept by using methacrylated gelatin to create a micropatterned hydrogel and 
subsequently seeded the construct with cardiomyocytes.[131] As seen in Figure 4A, this 
micropatterning produced cells with more regular beating characteristics, which is a quality 
that cardiomyocytes need to up hold in order for the heart to function properly. Along with 
micropatterning, microwells have also been shown to control the fate of stem cells due to the 
cells growing a spheroid bodies instead of in sheets. Recently, Yu-Shik et al. discovered that 
the size of the wells and, therefore, the size of the cell body grown influence which cell 
lineage stem cells differentiate into.[133] They used embryonic bodies for their study and 
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found that the larger the cell bodies exhibited cardiogenesis (Figure 4B) and the smaller cell 
bodies differentiated to an endothelial cell lineage. Another study compared the maturity of 
cardiomyocytes differentiated from human pluripotent stem cells (hPSCs) cultures in 2D 
sheets and 3D cardio-spheres.[134] As seen in the images of Figure 4C, the hPSCs that were 
grown as aggregates showed a significant increase in cardiomyocyte characteristics. 
Specifically, the cell aggregates produced more homogenous population of cardiomyocytes 
with better intracellular calcium transients and contractility. These studies provide further 
evidence that stem cell differentiation can be influenced by several environmental factors 
that scientists can use to their benefit for specific regenerative purposes.
Biomaterials strongly determine the limitations of these technologies.[145] Starting with 
silicon etching, microfluidic cardiac tissue engineering later evolved to use PDMS scaffolds, 
which ensure high fidelity and high feature resolution but offer only low cell attachment. 
Annabi et al. devised a method to coat the PDMS channel walls with tropoelastin-based 
hydrogel layer and observed an increase in cell attachment.[135] Increase in cell attachment 
levels led them to anticipate that the method may be useful to produce elastic tissues such as 
blood vessels.[135] However, since PDMS is not biodegradable, some applications moved to 
poly(lactide coglycolide) PLG and polyglycerol sebacate (PGS).[129] PGS is believed by 
some to be superior in properties to PLG, because the latter swells in vivo and causes 
chronic inflammation while PGS degrades slowly mainly due to surface erosion.[136] An 
application involving PGS with a built-in vascular network showed the successful 
biodegradation of PGS with an infiltration of host cells into the vessel network but without 
any immediate anastomosis upon implantation.[137] Hydrogels were also introduced into 
these applications, which provided several advantages since they allow large biomolecule 
and gas exchange, remove the 3D constraints on cell interaction,[129] as well as, facilitate the 
control over the physical, mechanical and biological microenvironments.[130]
The microfluidic and micropatterning techniques mentioned in this section offer a valuable 
strategy to solve the common problem in tissue engineering of inadequate 
vascularization.[146,147] The spatial control over biomaterials, cells, and biomolecules 
provides the opportunity for scientists to engineer a tissue construct with a vasculature 
network more indicative of native myocardium prior to implantation. This increases the 
chances for success in the treatment by reducing cell death due to lack of proper oxygen, 
waste, and nutrient transport. Hydrogels are the most common biomaterials used today for 
microfluidic applications in cardiac tissue engineering, however, challenges still remain in 
finding the biomaterial that is superior in all the characteristics needed for microfluidic 
devices. Furthermore, although this technology has made great strides, concerns still remain 
in inadequate engraftment of cardiac patches after transplantation. Lastly, in order for 
cardiac patches to become clinically viable the thickness of the patches must increase while 
still maintaining the mature prevascularization discussed in this section.
 7. Conclusion and Future Outlook
Research for cardiac tissue engineering and regenerative medicine with stem cells is greatly 
advancing with the use of biocompatible materials further increasing their therapeutic 
efficacy. Accessible sources of stem cells for cardiac applications have been located but their 
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survival in vivo after specialization has been continuously reported to be modest. Several 
types of stem cells have been identified: embryonic stem cells which are subject to ethical 
issues, adult stem cells which are difficult to locate, extract and separate from their 
heterogeneous environment and iPSCs which are easily accessible, expandable, patient 
specific and have so far proven to have therapeutic potential. Moreover, the challenge of 
translating these cell types into a clinical setting in a timely and cost effective manner still 
remains. Studies have shown that combining multiple cell types with growth factors in 
cardiac therapies generates better results, however, there still has not been a specific 
combination that has had adequate regenerative capacity for clinical translation. In addition, 
recently the hypothesis that paracrine factors are the primary mediators of cardiac 
regeneration by stem cells has gained support among scientists. However, there are still 
many unknown paracrine and differentiation mechanisms regarding stem cell behavior in the 
cardiac microenvironment. Future studies dedicated to understanding these mechanisms 
would provide valuable insight into treatment parameters and designs. Choosing the optimal 
route is crucial for a successful treatment, and is done based on the specific clinical case. 
Among the available routes for stem cell delivery (intracoronary, intravenous, 
intramyocardial, retrograde coronary sinus and intrapericardial), the predominant delivery 
methods in clinical trials today are intracoronary and intramural route of administration. In 
tissue engineering, the different methodologies that combine cells and materials (cell sheets, 
porous scaffolds, injectable hydrogels, cell surface engineering, and microcapsules) have 
each succeeded in enhancing cardiac repair. Nevertheless, in order to make these treatments 
easier to translate into the clinical setting the development of minimally invasive delivery 
techniques will be important. The main issues remain with improving the electrical, 
chemical and biomechanical properties of the cardiac construct to match those of the heart 
as well as increase the functionality and speed of formation of the vessel network within the 
construct. Bioreactors, which are designed to test the prepared cell cultures by simulating the 
in vivo environment, allow for improvement of the construct designs within labs. However, 
they are still too sophisticated to enter mass production. Future studies are turned toward 
understanding the behavior of the cultured stem cells in 3D constructs and controlling their 
environment through time and space. Recent advances in cardiac repair are directed at 
designing patient-specific supports for clinical applications. While no generally accepted 
solution for stem cell based cardiac therapy has been reached yet, the field of research is 
advancing quickly with more promising technology and results.
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Biomaterial-based approaches for improved cardiac stem cell therapy. A) MDSC sheet 
formed using temperature-responsive polymer (poly(N-isopropylacrylamide).[84] (i) Cell 
sheet containing MDSCs transduced with LacZ. (ii) Quantification of live LacZ-positive 12 
weeks after implantation. (*p < 0.05 vs control, #p < 0.05 vs injection). (iii) Immunostaining 
of infarcted area for fsMHC-positive (green) in close proximity to Lac-Z-transduced MDSCs 
(white arrows) 12 weeks after implantation of MDSC sheet to show skeletal muscle-like 
formation. Scale bar: 50 µm. B) N-isopropylacrylamide, N-acryloxysuccinimide, acrylic 
acid, and poly (trimethylene carbonate)-hydroxyethyl methacrylate injectable 
thermosensitive hydrogel synthesized to improve MSC differentiation to cardiac cells.[89] (i) 
Hasan et al. Page 26













Image of hydrogel solution at 4 °C (top) and solid gel at 37 °C (bottom). (ii) Stress–strain 
curve for hydrogels with different concentrations of the three polymers. (iii) Cardiac gene 
cnT1 expression for MSCs affected by hydrogel moduli on hydrogels with varying 
concentration of the three polymers. (10% = 16 kPa, 20% = 45 kPa, and 40% = 65 kPa) (p < 
0.05). C) Effect of NIPAAM/AAc/HEMA-oHB6 hydrogel and electrospun polyurethane 
fiber scaffold on cardiosphere-derived cell differentiation.[78] (i) Scaffold parameters for 
each of the four test groups. (ii) SEM image of each scaffold. (ii) cTnI expression (green) of 
CDCs in tissue constructs after 7 d of culture. Cell nuclei were stained by Hoechst (blue). 
Abbreviations: fsMHC, fast-skeletal myosin heavy chain; cnT1, cardiac troponin I; MDSC, 
muscle-derived stem cell; MSC, mesenchymal stem cell; VEGF, vascular endothelial growth 
factor; fsMDSC, fast skeletal myosin heavy chain; SEM, scanning electron microscopy.
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Biomaterial-based delivery systems for enhanced cardiac stem cell therapy. A) Modified 
MSCs using biotinylated lipid vesicles for systemic cell targeting.[104] (i) Schematic of 
vesicle formation and MSC modification. (ii) Effect of shear stress on percentage of cell 
interactions with the P-selectin coated surface in a flow chamber assay at 0.5 dyn cm−2 . B) 
Microencapsulated stem cells for myocardial infarction therapy.[113] (i) hASCs encapsulated 
in alginate-based microcapsules. Scale bar: 50 µm. (ii, iii) Microencapsulated stem cells, 
genetically modified to express GFP (transduced with only baculovirus or PAMAM 
dendrimer coated baculovirus), under fluorescence microscope on day 2 post encapsulation. 
The white circles show the peripheral surface of the microcapsules. Scale bar: 100 µm. (iv) 
Photograph shows direct intramyocardial delivery of microencapsulated hASCs to the peri-
infarct sites of rat heart. This strategy results in an improved cell retention, rapid 
angiogenesis, and improved cardiac function. Abbreviations: MSC, mesenchymel stem cell; 
hASCs, human adipose-derived stem cells; PAMAM, polyamidoamine; VEGF, vascular 
endothelial growth factor; PEG, polyethelene glycol; GFP, green fluorescent protein.
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Mechanobiology to control stem cell. A) Characterization of ECM-fibrin gels with varying 
concentrations of TG.[101] (i) Young’s modulus of gels produced by uniaxial testing. (ii) 
Swelling ratio. (iii) Cardiovascular gene expression of smooth muscle marker CNN1 and 
endothelial in gels with either neonatal ECM or adult ECM 21 d after cardiac progenitor cell 
seeding. B) (i) Anistroic fiber morphology shown in 2000× SEM micrograph of poly(ester 
carbonate urethane) electrospun scaffold.[123] (ii, iii) Z-stack confocal images of tissue 
constructs at different strains (0% and 75%). Rhodamine phalloidin was used to stain F-
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actins of the cells. Scale bar: 20 µm (iv, v) Real time RT-PCR analysis of cardiac specific 
genes GATA4 and Nkx 2.5. Control group represents the gene expression of MSCs culture 
on tissue culture plates. Control group values were used for normalization. Abbreviations: 
SEM, scanning electron microscopy; RT-PCR, reverse transcription polymerase chain 
reaction; TG, transglutaminase; ECM, extracellular matrix; CNN1, calponin 1.
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Microscale techniques for controlling stem cell behavior. A) (i) Optical profilometry of 
patterned 67% PD gelatin hydrogel. A) (ii) Cardiomyocyte beating characteristic of 
unpatterned and patterned gelatin gels at varying PD concentrations. Pixel intensity was used 
to monitor the gels over a 30 s period [131] B) (i, ii) Morphology of beating EBs, 
immunocytochemical characterization of cardiomyogenic differentiation identified by 
sarcomeric α-actinin and evaluation of beating EBs cultured in microwells. Inset for 150 µm 
EB figure indicates control stained only with secondary antibody. Scale bar: 100 µm.[133] C) 
Immunostaining for sarcomeric α-actinin (green) and nuclei (blue) of three different 
pluripotent cell sources harvested from day 21 monolayer cultures and day 7 
cardiosphere.[138] Scale bars: 50 µm. Abbreviations: hiPSC, human induced pluripotent stem 
cell; hESCs, human embryonic stem cell; PD, photodegradable; EB, embryonic bodies.
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Table 1
Advantages and drawbacks of different types of stem cells, delivery methods and fabricated biomaterials used.




Very sensitive to temperature
and pH changes
Bone marrow derived adult
stem cells







Isolation is required due
to heterogeneous cell
population
Adipose derived adult stem
cells
Less invasive and painful
surgery












Endothelial progenitor Production of large
amounts of growth factors
and cytokines
Rare population [31,140]
Delivery methods Advantages Drawbacks Ref.
Intracoronary No risk of systemic
delivery
Low cell delivery [35]
Direct delivery
Intravenous Not invasive Cells can be isolated in
lung, liver or spleen
[36,38,141]
Intramyocardial Direct delivery Perforation risk [43]





Retrograde coronary sinus Homogeneous cell delivery Endothelial wall transmigration
required
[48]
Biomaterials Advantages Possible concerns Ref.
Cell sheets Long-term survival
and growth rate after
implementation








properties of the injected
materials
[142]
Porous scaffolds Increased Vascularization Biodegradation properties [92]
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Table 2
Different types of bioreactors for cardiac tissue engineering.
Bioreactors Culture type Advantages Examples Ref.
Perfusion Scaffolds Enhances mass transfer of oxygen
through the engineered patch
Vascular cells reveal changes
in their metabolic and
functional properties after
exposure to increased levels
of shear stress, as well as
increased cell distribution and
lower diffusion gradients
[120,143]
Creates frictional shear stress




Scaffolds Delivers different shear stresses at
the same time
DNA content of cultured cells
increases by 91% after exposure
to the bioreactor
[120]
Can be used on 3D tissues
Pulsatile fow Cell-Sheets Enhances vascularization of stacked
cell sheets
Stacking of six layers of rat
cardiac cell sheets resulted in
a thicker and denser grafts,
which contracts regularly after




Scaffolds Increases cardiomyocyte size Human cardiac constructs
implanted into rats after exposure
to uniaxial loading displayed
increased active force
and enhanced graft perfusion
into host tissue
[120]






Creates laminar fluid flow Cardiomyocytes cultured in
these bioreactors have a constant
pH, %CO2, and %O2, compared
to an increasing amount
of DNA in the culture.
[143]





Ensures impulse propagation Cardiac constructs propagate
continuous pulses and a
rate of 400 beats min−1 after
inserting in an electrical
stimulation bioreactor
[144]
Increased conduction velocities to
mimic in vitro conditions
Caused synchronous macroscopic
pulses
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